Avalanche Biotechnologies Header Image: Iris
Sustained Therapeutic delivery for the eye

Gaining Momentum in the Treatment of Eye Disease

Avalanche is a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases. Using a next generation gene therapy platform, the Ocular BioFactory™, the Company is developing products designed to provide long-term benefit or a functional cure by inducing a sustained expression of a therapeutic protein with a one-time administration in the eye.

Read More

Avalanche Biotechnologies to Present at the Jefferies Global Healthcare Conference

November 13, 2014

MENLO PARK, CA – November 13, 2014 – Avalanche Biotechnologies, Inc. (Nasdaq: AAVL), a clinical-stage biotechnology company focused on discovering and developing novel gene therapies to transform the lives of patients with sight-threatening ophthalmic diseases, today announced that Linda C. Bain, Chief Financial Officer, will present at the Jefferies Global Healthcare Conference on Thursday, November 20, 2014 at 8:40 am GMT in London, England.

Read More

Read All Avalanche News